ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LFMD
NAKA (18) AIRS (33) BMGL (53) ALPS (52) ⌘ Pro Terminal →

LifeMD Inc. (LFMD) — RQD Stock Rating Cockpit

$2.31 +0.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.31

LifeMD Inc. (LFMD) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $110.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, LifeMD Inc. (NASDAQ: LFMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.31 (+0.87% 1D, market cap $110.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFMD ranks #722 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFMD compare to NAKA and AIRS in the Health Care sector?
▼

Within the Health Care sector (Medical/Nursing Services), LFMD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 85.7%, and ROIC of -26.2%. By comparison, NAKA (Nakamoto Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -31.6%, cap $107.5M) and AIRS (AirSculpt Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.0%, cap $124.7M). Among the 5-stock peer group, LFMD leads on earnings multiple (N/A) while AIRS leads on capital efficiency (-7.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFMD?
▼

Per LFMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000948320), LifeMD Inc. generated $194.1M in revenue (+25.3% YoY), -$11.2M in net income, and $6.4M in free cash flow against $70.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.31 (-0.03%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (8)Whales (3)SEC (5)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$6 Bull$2 Base$2 Bear
📬 FREE LFMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFMD)Realized 20D OHLCV Swing Band: ±11.4%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY LFMD SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (-0.40% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 3.3% FCF Margin ($6.4M FCF) & 85.7% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$2.47-8.9% Next Q
Q2 (-2Q)
37
Grade E$2.25-5.8% Next Q
Q3 (-1Q)
35
Grade E$2.12+9% Next Q
Current
32
Grade E$2.31-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LFMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LFMD currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.78) and Max Pain ($2.43) forces dealer call-delta covering toward $6.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LFMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
39.430 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $2$2.31H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LFMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-26.2% ROIC with 85.7% gross margin and 5.73% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 0.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (32)

12/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like LFMD
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LFMD)

  • ✓Walkthrough of LFMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LFMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.62%▼ DESCENDING CHANNEL
2026-11-03O $2.32H $2.32L $2.29C $2.31VOL 599.1K
RES: $2.83SUP: $1.96SMA50: $2.78SMA200: $3.65
$5.61$4.65$3.69$2.72$1.76RES $2.83SUP $1.96$2.312026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFMD Butterfly Map → + Track LFMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +25.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LFMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LFMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFMD)

Health Care Rank #722 of 1015 ⚔️ NAKA vs LFMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFMD vs. NAKA, AIRS, BMGL, ALPS)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, LifeMD Inc. (LFMD) ranks #722 by composite RQD confidence (32/100, grade E) and #636 by equity capitalization ($110.4M). Within this direct 5-issuer industry benchmark cohort, LFMD leads on earnings valuation at N/A trailing P/E, while AIRS leads on capital efficiency and profitability with -7.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with LFMD at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LFMD ACTIVE
LifeMD Inc.
E 32/100 — 85.7% -26.2% +0.87% $110.4M Benchmark Subject
NAKA
Nakamoto Inc.
E 18/100 — — -31.6% -5.46% $107.5M /naka-vs-lfmd →
AIRS
AirSculpt Technologies Inc.
E 33/100 — — -7.0% -3.47% $124.7M /airs-vs-lfmd →
BMGL
Basel Medical Group Ltd
D+ 53/100 — — — +1.39% $68.5M /bmgl-vs-lfmd →
ALPS
ALPS Group Inc Ordinary Share
D+ 52/100 — — — -0.21% $54.1M /alps-vs-lfmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000948320 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LifeMD Inc. (LFMD) reported GAAP revenue of $194.1M (+25.3% vs. FY2024 revenue of $154.8M , and +27.2% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of $8.3M, and free cash flow of $6.4M (-60.1% YoY). On the balance sheet, LFMD closed FY2025 with $70.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $194.1M -$11.2M $8.3M $6.4M $70.4M —
FY2024 (FY) 2024-12-31 $154.8M $24.5M $17.5M $16.0M $76.1M —
FY2023 (FY) 2023-12-31 $152.5M $17.8M $8.8M $8.8M — —

3. LFMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, LifeMD Inc. (NASDAQ: LFMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.31 (+0.87% 1D, market cap $110.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFMD ranks #722 in composite RQD confidence.

How does LFMD compare to NAKA and AIRS in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), LFMD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 85.7%, and ROIC of -26.2%. By comparison, NAKA (Nakamoto Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -31.6%, cap $107.5M) and AIRS (AirSculpt Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.0%, cap $124.7M). Among the 5-stock peer group, LFMD leads on earnings multiple (N/A) while AIRS leads on capital efficiency (-7.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LFMD?

Per LFMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000948320), LifeMD Inc. generated $194.1M in revenue (+25.3% YoY), -$11.2M in net income, and $6.4M in free cash flow against $70.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LFMD trading relative to its 50-day, 200-day, and 52-week technical levels?

LFMD last traded at $2.31 (+0.87% on volume of 635,901 shares), positioning the stock -16.91% below its 50-day simple moving average ($2.78) and -36.71% below its 200-day simple moving average ($3.65). Across its 52-week range of $2.06 to $5.96, LFMD sits at the 6.4% percentile with a 14-day RSI of 39.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($2.05 to $2.57).

Direct Sub-Reports: LFMD RQD Cockpit LFMD 12M Forecast LFMD Earnings & Move LFMD Dividends & DRIP LFMD Insiders & 13F LFMD Whale Options LFMD Profit Sankey LFMD News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

LFMD — LifeMD Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

LifeMD Inc. (LFMD) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.31 (+0.87% 1D, market capitalization $110.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -26.2%, gross margin of 85.7%, operating margin of -4.0%, and free cash flow yield of 5.73%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

LifeMD Inc. Is a NASDAQ-listed issuer classified in the Health Care sector and the Medical/Nursing Services industry. Per the market data, the company reports a gross margin of 85.7%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), LifeMD Inc. (LFMD) reported $194.1M in annual revenue (up from $154.8M in FY2024, +25.3% YoY) and -$11.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($152.5M revenue, $17.8M net income) through FY2025, LFMD scaled operating cash flow to $8.3M and free cash flow to $6.4M, backed by $70.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 5.73% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.06 – $5.96 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -4.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded for LFMD. Sector classification is Health Care / Medical/Nursing Services. The only sector-level ripple visible in the source is the RED-tagged MDxHealth item, which describes a revenue miss and guidance suspension at a different issuer; investors may treat this as a sentiment signal for the broader sector rather than a documented LFMD linkage.

  • Key Question #1: Can LFMD sustain or expand its -4.0% operating margin and -26.2% ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $194.1M and free cash flow of $6.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LFMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LFMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LifeMD Inc. (LFMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFMD Bull vs. Bear Conversation Board — What's Your Call at $2.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LFMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $2.63 (+14.8%)
📌 Pinned Debate

Revenue grew from $152.5M in FY 2023 to $194.1M in FY 2025 while FCF yield stands at 5.73%.

Revenue grew from $152.5M in FY 2023 to $194.1M in FY 2025 while FCF yield stands at 5.73%.. When you look under the hood at LFMD, Fundamental Cash Engine is 8/20 with 85.7% gross margins and -26.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $5.96. My 12M target is $2.63.

RetailWhale_TX 🐂 BULL

Both sides have a point here — LFMD's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.95 (-14.8%)
Spot @ $2.29

Altman Z of 0.2 and ROIC of -26.2% signal forensic balance-sheet and returns risk per the RQD rating.

Altman Z of 0.2 and ROIC of -26.2% signal forensic balance-sheet and returns risk per the RQD rating.. Look at the math on LFMD: paying current EV/EBITDA multiples for -26.2% ROIC and -4.0% operating margins leaves zero margin of safety if Medical/Nursing Services demand softens. I'd wait for a retest of $2.02 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%